Evidence map›Paper›PMID 38879735›Full record

ArticleClinical and experimental nephrology2024

Adverse reactions and effects on renal function of COVID-19 vaccines in patients with IgA nephropathy.

Katsushi Nagatsuji, Takashi Morikawa, Natsuki Ide, Ryuichi Kunishige, Shiho Takahata, Aoi Matsuki, Keita Kadosawa, Yuko Sakata, Daisuke Yamazaki, Mikiko Shibata and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Katsushi NagatsujiDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Takashi MorikawaDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Natsuki IdeDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Ryuichi KunishigeDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Shiho TakahataDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Aoi MatsukiDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Keita KadosawaDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Yuko SakataDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Daisuke YamazakiDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Mikiko ShibataPreventive Medicine and Environmental Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Masahiro HamadaDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Chizuko KitabayashiDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan.
Akira NishiyamaDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan.
Yoshio KonishiDepartment of Nephrology and Hypertension, Osaka City General Hospital, 2-13-22 Miyakojima-hondori Miyakojima-ku, Osaka, 534-0021, Japan. y-konishi@med.osakacity-hp.or.jp.ORCID http://orcid.org/0009-0006-2029-8977

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough vaccination has been reported to reduce the morbidity and severity of COVID-19 infection in patients with kidney disease, gross hematuria is frequently reported following vaccination in patients with IgA nephropathy. We investigated the frequency of gross hematuria following COVID-19 vaccination and its effect on renal function in IgA nephropathy patients.

methodsAdverse reactions after two or more COVID-19 vaccine doses were investigated in 295 IgA nephropathy patients attending Osaka Cty general hospital from September 2021 to November 2022. We compared differences in background characteristics and other adverse reactions between groups with and without gross hematuria after vaccination, and examined changes in renal function and proteinuria.

resultsTwenty-eight patients (9.5%) had gross hematuria. The median age of patients with and without gross hematuria was 44 (29-48) and 49 (42-61) years, respectively, indicating a significant difference. The percentage of patients with microscopic hematuria before vaccination differed significantly between those with (65.2%) and without (32%) gross hematuria. Adverse reactions, such as fever, chills, headache and arthralgia, were more frequent in patients with gross hematuria. There was no difference in renal functional decline after approximately 1 year between patients with and without gross hematuria. We also found no significant changes in estimated glomerular filtration rate or proteinuria before and after vaccination in the gross hematuria group. However, some patients clearly had worsening of renal function.

conclusionsWhile COVID-19 vaccination is beneficial, care is required since it might adversely affect renal function in some patients.

Indexed as

COVID-19COVID-19 VaccinesGlomerular Filtration RateGlomerulonephritis, IGAHematuriaKidneyAdultFemaleHumansMaleMiddle AgedProteinuriaSARS-CoV-2COVID-19 VaccinesCOVID-19 vaccinationGross hematuriaIgA nephropathy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.